Rising Demand For Precision Medicine: A Key Driver In the Single-Molecule Real-Time Sequencing (SMRT) Market 2024

December 17, 2024 12:30 AM AEDT | By EIN Presswire
 Rising Demand For Precision Medicine: A Key Driver In the Single-Molecule Real-Time Sequencing (SMRT) Market 2024
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, December 16, 2024 /EINPresswire.com/ -- The Business Research Company’s Early Year-End Sale! Get up to 30% off detailed market research reports—limited time only!

What is the Projected Growth of the Single-Molecule Real-Time Sequencing SMRT Market?

The single-molecule real-time sequencing SMRT market size has experienced substantial growth in recent years. The market is forecasted to rise from $2.89 billion in 2023 to $3.11 billion in 2024, signifying a compound annual growth rate CAGR of 7.7%. This growth during the historic period can be credited to the growing prevalence of genetic disorders, disease-causing mutations identification, the unraveling intricacies of gene regulation, the exploration of new frontiers in genetic and molecular biology, and the increasing emphasis on genomics research.

Are you curious to learn more about the SMRT market growth? Check out a detailed sample report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19696&type=smp

What Will Influence the SMRT Market in the Upcoming Years?

The single-molecule real-time sequencing SMRT market size is anticipated to see robust growth in the next few years. It is expected to grow to $4.22 billion in 2028 at a compound annual growth rate CAGR of 8.0%. The growth in the forecast period can be attributed to the rising demand for precision medicine, the ongoing study of genetics and molecular biology, the necessity for high throughput sequencing technologies, and the increasing requirement for long read lengths and high accuracy for studying complex genetic structures. Additionally, major advancements such as expansion into clinical diagnostics, the development of novel applications, innovations in next-generation sequencing NGS, improvements in data analysis for interpretation and application of sequencing results, and product innovations are set to shape the market in the coming years.

Do you wish to acquire the entire report? Here is your chance: https://www.thebusinessresearchcompany.com/report/single-molecule-real-time-sequencing-smrt-global-market-report

What’s Driving Growth in the SMRT Market?

The rising demand for precision medicine is expected to propel the growth of the single-molecule real-time sequencing SMRT market going forward. Precision medicine, also known as personalized medicine, is a unique approach that customizes treatment and healthcare strategies for individuals based on their genetic, environmental, and lifestyle factors. The growing demand for personalized medicine, fueled by advancements in genomic technologies, allows for more precise, tailored treatments and places a growing emphasis on individualized patient care for improved outcomes.

Which Are The Main Companies Operating in the SMRT Market?

Major companies operating in the single-molecule real-time sequencing SMRT market include Thermo Fisher Scientific Inc., Illumina Inc., Qiagen N.V., BGI Group, 10x Genomics Inc., Ginkgo Bioworks Inc., Oxford Nanopore Technologies Limited, Genewiz Inc., Pacific Biosciences of California Inc., Macrogen Inc., Element Biosciences Inc., Asuragen Inc., BioNano Genomics Inc., Zymo Research Corporation, Microsynth AG, GATC Biotech AG, Dovetail Genomics LLC, SeqWell Inc., Paragon Genomics Inc., and Nabsys Inc.

How Is the Global SMRT Market Segmented?

The single-molecule real-time sequencing SMRT market covered in this report is segmented as follows:

1 By Product: Consumable, Instrument, Services
2 By Application: DNA Sequencing, RNA Sequencing, Epigenetics, Whole Genome Sequencing, Other Applications
3 By End-Users: Hospitals, Diagnostic Laboratories, Biopharmaceutical Companies, Academic Institutes And Research Centers, Other End-Users

What Is the Regional Landscape of the SMRT Market?

North America was the largest region in the single-molecule real-time sequencing SMRT market in 2023. The regions covered in the single-molecule real-time sequencing SMRT market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:
Migraine Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report
Molecular Biology Enzymes & Kits & Reagents Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/molecular-biology-enzymes-and-kits-and-reagents-global-market-report
Neuroscience Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/](https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company](https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ](https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model](https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.